Insmed Incorporated (INSM)
NASDAQ: INSM · Real-Time Price · USD
98.18
+1.52 (1.57%)
At close: Jul 11, 2025, 4:00 PM
98.50
+0.32 (0.33%)
After-hours: Jul 11, 2025, 7:48 PM EDT
Insmed Revenue
Insmed had revenue of $92.82M in the quarter ending March 31, 2025, with 22.94% growth. This brings the company's revenue in the last twelve months to $381.03M, up 20.77% year-over-year. In the year 2024, Insmed had annual revenue of $363.71M with 19.17% growth.
Revenue (ttm)
$381.03M
Revenue Growth
+20.77%
P/S Ratio
44.36
Revenue / Employee
$299,788
Employees
1,271
Market Cap
18.65B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 363.71M | 58.50M | 19.17% |
| Dec 31, 2023 | 305.21M | 59.85M | 24.39% |
| Dec 31, 2022 | 245.36M | 56.90M | 30.19% |
| Dec 31, 2021 | 188.46M | 24.05M | 14.63% |
| Dec 31, 2020 | 164.41M | 27.95M | 20.48% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.98B |
| Novartis AG | 53.22B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
INSM News
- 26 days ago - Is Insmed Stock Overvalued After The 45% Jump? - Forbes
- 4 weeks ago - Insmed Announces Pricing of $750 Million Public Offering of Common Stock - PRNewsWire
- 4 weeks ago - Insmed Announces Proposed $650 Million Public Offering of Common Stock - PRNewsWire
- 4 weeks ago - Insmed's Pulmonary Hypertension Drug Data Exceeded Even Bullish Outlook, Analysts Boost Price Forecast - Benzinga
- 4 weeks ago - Insmed: Company Presses On With Further POC PAH Treatment Data - Seeking Alpha
- 4 weeks ago - Insmed's blood pressure drug meets main goal in mid-stage trial - Reuters
- 4 weeks ago - Insmed Announces Positive Topline Results from Phase 2b Study of Treprostinil Palmitil Inhalation Powder (TPIP) as Once-Daily Therapy in Patients with Pulmonary Arterial Hypertension - PRNewsWire
- 5 weeks ago - Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - PRNewsWire